Nervous system

Saquon Barkley Enhances Recovery from Torn ACL with Neuromuscular Stimulation

Retrieved on: 
Monday, September 27, 2021
Therapy, ACL, Trauma, Chronic pain, Chicago, Nervous system, Health, Injury, FDA, Patient, Salpeter, Athlete, Chicago Bears, CEO, Rehabilitation, Neurology, Pain, Motion, Love, Meniscus, Research, Atrophy, University, Accident, Muscle, Hospital, Satellite navigation device, Dentistry

AUSTIN, Texas, Sept. 27, 2021 /PRNewswire/ -- NeuFit , a provider of advanced neuromuscular treatment for patients and athletes, announced that professional running back, Saquon Barkley, has successfully used the company's Neubie device as a part of his recovery from ACL and meniscus surgery.

Key Points: 
  • AUSTIN, Texas, Sept. 27, 2021 /PRNewswire/ -- NeuFit , a provider of advanced neuromuscular treatment for patients and athletes, announced that professional running back, Saquon Barkley, has successfully used the company's Neubie device as a part of his recovery from ACL and meniscus surgery.
  • During a game against the Chicago Bears in week 2 of the 2020-2021 season, Barkley tore his ACL and meniscus.
  • Barkley was facing a long road of recovery ahead of him.
  • It is not uncommon for athletes in peak physical condition to require many months after ACL surgery before they can return to play a sport competitively.

Poxel Announces its Participation at Upcoming Scientific Conferences Related to Adrenoleukodystrophy (ALD)

Retrieved on: 
Monday, September 27, 2021
Research, Diabetes, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, HSCT, Man, Sex linkage, Weakness, Senior, Metabolism, Peroxisome, Death, Growth, POC, Cell, Incontinence, Scientific communication, ALD, Euronext Paris, Lists of diseases, NASH, Disease, Peripheral nervous system, AMN, VLCFA, Conditional sentence, Fatty liver disease, Pharmacology, Metabolic disorder, Exocrine gland, Partnership, Évian-les-Bains, Degenerative disease, White matter, ABCD1, Spinal cord, Company, Adrenoleukodystrophy, Woman, Risk, Gait, Brain, Haemophilia, R, Forward-looking statement, Doctor of Philosophy, Treatment, Chronic inflammatory demyelinating polyneuropathy, Nervous system, Sumitomo Dainippon Pharma, Euronext, Patient, Hematopoietic stem cell transplantation, Hotel manager, AMPK, Prevalence, Pharmaceutical industry, Medical device, ALD, Poxel SA, ALD, POXEL SA

POXEL SA (Euronext POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Poxel team will participate at several upcoming scientific conferences related to X-linked adrenoleukodystrophy (ALD), a severe orphan neurometabolic disease with no approved therapies.

Key Points: 
  • POXEL SA (Euronext POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Poxel team will participate at several upcoming scientific conferences related to X-linked adrenoleukodystrophy (ALD), a severe orphan neurometabolic disease with no approved therapies.
  • Poxel's scientific team will present data and plans pertaining to ALD that align with the recently announced new strategic direction of increasing Poxels focus on rare metabolic diseases.
  • Poxel is committed to focus its pipeline on high value, rare metabolic indications and NASH, with the goal of creating pipeline synergies, maximizing resources, and driving shareholder value.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Poxel Reports Financial Results for First Half 2021 and Provides a Corporate Update

Retrieved on: 
Thursday, September 23, 2021
Research, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, EUR, Goal, Type 2 diabetes, Trial, Senior, Program, POC, ILC, Scientific communication, Chronic kidney disease, Director, ALD, TIMES, Inflammation, Investor relations, JPY, Lists of diseases, Association, Public relations, Adult, NASH, CEO, European Association for the Study of the Liver, Disease, Drug development, Male, AMN, VLCFA, Conditional sentence, Fatty liver disease, United Nations Scientific Committee on the Effects of Atomic Radiation, Pharmacology, Plasma, Tablet, EASL, Exocrine gland, Corporate communication, USD, Achievement, FXR, Therapy, Degenerative disease, Adrenoleukodystrophy, R, Pharmacokinetics, Nervous system, Sumitomo Dainippon Pharma, Euronext, Annual, Patient, Metaves, Imeglimin, Biomarker, Board, AMPK, IPF, Efficacy, CKD, Pharmaceutical industry, Medical device, Management

This achievement has strengthened our near-term financial position and will continue to enhance our financial foundation with associated future royalties and sales-based payments, said Thomas Kuhn, CEO of Poxel.

Key Points: 
  • This achievement has strengthened our near-term financial position and will continue to enhance our financial foundation with associated future royalties and sales-based payments, said Thomas Kuhn, CEO of Poxel.
  • Poxel is well-positioned to leverage its existing platforms to develop therapeutics in rare metabolic diseases, Mr. Kuhn concluded.
  • In July 2021, Poxel received a milestone payment of JPY 1.75 billion (approximately EUR 13.2 million, USD 15.8 million)1 from Sumitomo Dainippon Pharma.
  • Revenue for the first half of 2021 mostly reflects the JPY 1.75 billion (EUR 13.2 million) milestone payment from Sumitomo Dainippon Pharma which Poxel received in July 2021.

GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021

Retrieved on: 
Thursday, September 23, 2021
Technology, Medical Devices, Genetics, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, CNS, CRISPR, Polymer, Sequoia Capital, Korea, Nervous system, Eli Lilly, RNA, Beckman Center for Molecular and Genetic Medicine, DNA, Patient, Central nervous system, SK Group, Company, Tissue, Cell, Nanoparticle, Pharmaceutical industry, Vaccine

In addition, GenEdit today disclosed new in vivo data demonstrating tissue-selective delivery after intravenous or intrathecal administration of its polymer nanoparticles.

Key Points: 
  • In addition, GenEdit today disclosed new in vivo data demonstrating tissue-selective delivery after intravenous or intrathecal administration of its polymer nanoparticles.
  • Additional data show GenEdits polymer nanoparticles can be dosed multiple times with functional activity of the payload maintained in each subsequent dose.
  • With this financing, we are exploring the universe of opportunities within GenEdits NanoGalaxy platform to treat serious diseases without effective treatment options, said Dr. Lee.
  • At GenEdit, our mission is to develop curative therapies through targeted in vivo delivery of genetic medicines.

Redpin Therapeutics Receives Four Additional US Patents

Retrieved on: 
Wednesday, September 22, 2021
Therapy, Ion channel, Nervous system, Howard Hughes Medical Institute, Chemogenetics, FDA, Varenicline, Patient, Ion, Central nervous system, Method, Lists of diseases, Disease, Founder, Technology, Drug development, Synthetic biology, Cell, United States patent law, Protein, Patent, Neuron, Pharmaceutical industry

We are delighted to have further strengthened the patent estate around our groundbreaking ultra-potent ion channel based chemogenetics platform, said Dr. Elma Hawkins, President and Founder of Redpin Therapeutics.

Key Points: 
  • We are delighted to have further strengthened the patent estate around our groundbreaking ultra-potent ion channel based chemogenetics platform, said Dr. Elma Hawkins, President and Founder of Redpin Therapeutics.
  • These patents added to our existing estate will ensure that we can bring targeted cell therapies to patients in need as rapidly as possible.
  • These four additional patents provide broad coverage, until 2038, for a class of modified ligand-gated ion channels that are based on the ligand binding domain of the nicotinic acetylcholine receptor and methods of their use.
  • Redpin is building an innovative ion channel-based chemogenetics platform that introduces a new paradigm for tunable, targeted cell therapies.

Ehave Appoints Board-Certified Gastroenterologist And Licensed Physician Dr. Rahul Dixit To Its Medical Advisory Board

Retrieved on: 
Tuesday, September 21, 2021
Biotechnology, Herbal, Phi Beta Kappa Award in Science, Johns Hopkins Hospital, IBS, Lists of diseases, Artificial intelligence, Failure, Nervous system, Risk, Security (finance), Therapy, Privacy, Private Securities Litigation Reform Act, OTC Markets Group, U.S. Securities and Exchange Commission, Depression, Overalls, HIPAA, Patient, USA, Population, University of Maryland School of Medicine, MD, Health, American Board of Commissioners for Foreign Missions, Ascension (company), Maryland School, Form, CEO, University, Company, Internal medicine, LA, Mental health, Dixit, Intelligence, Cannabis, American Board of Internal Medicine, G Plan, Research, Irritable bowel syndrome, Forward-looking statement, Machine learning, SEC, GLOBE, Pharmaceutical industry, Medical device

Rahul Dixit, MD Dr. Rahul Dixit, MD is a Gastroenterology Specialist with over 17 years of experience in the medical field.

Key Points: 
  • Rahul Dixit, MD Dr. Rahul Dixit, MD is a Gastroenterology Specialist with over 17 years of experience in the medical field.
  • As a student, Rahul Dixit accumulated numerous honors, including the Distinguished Medical Student Service Award.
  • Thanks to his outstanding academic achievements, he is one of the most sought out providers in the medical field.
  • Ben Kaplan, CEO of Ehave, Inc. said, Ehave is very fortunate to include such an esteemed medical professional as Dr. Dixit as a member of our Medical Advisory Board.

Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries

Retrieved on: 
Tuesday, September 21, 2021
Vomiting, Food, Safety, Journal of Clinical Anesthesia, Pharmacokinetics, Vein, PK, Nervous system, Liver disease, Peri, Degenerative disease, Pain management, Molecule, Length of stay, Hospital, Constipation, FDA, Surgeon, Patient, Allergy, Population, MD, Adult, Nausea, Time-invariant system, Hydrogen chloride, Joint, Profile, Bupivacaine, Anesthetic, Food and Drug Administration, Ageing, Child, Pain, PLAY, Anesthesiology, Fasciculation, Fever, AES, Pregnancy, Nicklaus Children's Hospital, Spine, Time, Industry, Plasma, GLOBE, Dentistry, Mineral wool, Pharmaceutical industry

PARSIPPANY, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that full results of its Phase 3 PLAY study of EXPAREL (bupivacaine liposome injectable suspension) administered via infiltration in pediatric patients undergoing spinal or cardiac surgeries have been published in Journal of Clinical Anesthesia .

Key Points: 
  • PARSIPPANY, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that full results of its Phase 3 PLAY study of EXPAREL (bupivacaine liposome injectable suspension) administered via infiltration in pediatric patients undergoing spinal or cardiac surgeries have been published in Journal of Clinical Anesthesia .
  • There were no treatment-related cardiac or nervous system adverse events (AEs) in the EXPAREL arm.
  • Additionally, AEs were mild to moderate, supporting the safety of EXPAREL in pediatric patients undergoing spine or cardiac surgery.
  • Results of this study build upon a growing body of evidence supporting the use of EXPAREL in pediatric procedures.

Rare Cannabinoid Company Launches World's First Pure CBDV Oil - Cannabidivarin Is Being Researched For Autism, Muscular Dystrophy, Rett Syndrome and Seizures

Retrieved on: 
Wednesday, September 22, 2021
People, THC, Autism spectrum, Cannabinol, Mouse, Sleep, RATS, Binary relation, Duchenne muscular dystrophy, Weight loss, Hope, Honey, Nervous system, Memory, Social skills, CBN, Inflammation, GW Pharmaceuticals, Cannabinoid, FDA, Locomotion, Map, Patient, Carbon, CBG, THCV, ASD, Physician, Muscular dystrophy, Nausea, CDC, Irritability, Sale, Nursing, Diabetes, CBC, Communication, Glia, Knowledge, CBDV, Growth, Disease, Risk, DMD, Ulcerative colitis, Human, Weight gain, Research, Rett syndrome, CBDA, Paranoia, Anxiety, Relaxation, Seizure, Pharmaceutical industry, Perfume

HONOLULU, Sept. 22, 2021 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company has launched the world's first pure CBDV oil for sale .

Key Points: 
  • HONOLULU, Sept. 22, 2021 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company has launched the world's first pure CBDV oil for sale .
  • While CBDV (cannabidivarin) sounds like CBD (cannabidiol), this varin variety is extremely rare and appears to have exciting potential.
  • In preclinical studies, it has shown potential for easing symptoms of ASD , Rett syndrome and muscular dystrophy .
  • Rare Cannabinoid company's sister brand, Hawaiian Choice , was established in 2017 and is the most popular CBD brand in Hawaii.

Pope Francis has blessed the cornerstone of new Saint Martin's Hospital - the first Slovak healthcare project funded by the EU Recovery and Resilience Plan

Retrieved on: 
Tuesday, September 21, 2021
Holy Mass Central School, Kollam, Mass in the Catholic Church, Health, Nervous system, Economic and Financial Affairs Council, Economy, Hospital, Heart, Recovery, Stadium MUDr. Ivan Chodák, Royal commission, Teaching hospital, MBA, Research, European Commission, Internal medicine, Education, Health insurance

"Blessing of the cornerstone of the new university hospital in Martin by Pope Francis is a great honour for us and at the same time a commitment to further work.

Key Points: 
  • "Blessing of the cornerstone of the new university hospital in Martin by Pope Francis is a great honour for us and at the same time a commitment to further work.
  • For the region of Central Slovakia, Saint Martin's University Hospital will represent a significant investment", stated MUDr.
  • The construction project of Saint Martin's University Hospital in Martin will be implemented in the timeframe of several years and has the potential to be one of the first materializations of the Recovery and Resilience Plan results".
  • Slovakia submitted the Recovery and Resilience Plan of the Slovak Republic as one of the first EU countries.

Global Lyme Alliance and DiaSorin Announce Partnership Seeking Study Volunteers to Advance an Innovative Lyme Disease Diagnostic

Retrieved on: 
Tuesday, September 21, 2021
Infection, Partnership, Borrelia burgdorferi, Diagnosis, Brown University, Nervous system, Risk, QuantiFERON, Fatigue, Deer, Immunity, FTSE, Immunoglobulin M, IGRA, Physician, Degenerative disease, CDC, Heart, Lyme disease, Marketing, DiaSorin, Joint, Volunteering, IVD, Group, Company, Antibody, Rash, Awareness, Disease, Lymph, Tick-Borne Disease Alliance, Research, Fever, Plasma, List of life sciences, GLA, Chills, Headache, Vector, Education, Vaccine, Tourism

This important study is seeking people who have been recently diagnosed with early-stage Lyme disease to participate.

Key Points: 
  • This important study is seeking people who have been recently diagnosed with early-stage Lyme disease to participate.
  • The current CDC-recommended two-tiered diagnostic is indirect, detecting antibodies made in response to the Lyme infection, not the detection of the Lyme disease bacteria (Borrelia burgdorferi) itself.
  • The earlier Lyme disease can be diagnosed, the better the patient outcome," says Global Lyme Alliance's Chief Scientific Officer, Timothy Sellati, Ph.D.
  • Global Lyme Alliance (GLA) is the leading 501(c)(3) dedicated to conquering Lyme disease through research, education, and patient services.